1 / 51

Educational Objectives

Educational Objectives. Metastatic Breast Cancer: Scope of the Problem. Metastatic Breast Cancer: General Treatment Considerations. Therapeutic Goals/Endpoints in MBC. MBC: Impact of Chemotherapy. Treatment Options for Advanced Breast Cancer. First-Line Chemotherapy Options.

mabyn
Download Presentation

Educational Objectives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Educational Objectives

  2. Metastatic Breast Cancer: Scope of the Problem

  3. Metastatic Breast Cancer: General Treatment Considerations

  4. Therapeutic Goals/Endpoints in MBC

  5. MBC: Impact of Chemotherapy

  6. Treatment Options for Advanced Breast Cancer

  7. First-Line Chemotherapy Options

  8. Response Rates with Single-AgentChemotherapeutic Agents in MBC

  9. Highlights of the Evolution of Taxanes in Oncology

  10. Taxanes in the Treatment of MBC

  11. Conventional Taxanes: Pharmacologic and Pharmacodynamic Differences

  12. Conventional Taxanes: Impact of Solvents

  13. Albumin Role: Natural Carrier ofHydrophobic Molecules in Humans

  14. Increased Intratumoral Concentration With nab-Paclitaxel

  15. Differentiating the Taxanes: Toxicity

  16. Making Taxanes Less “Tax-ing”

  17. Taxane Toxicities

  18. Randomized Comparison Between Taxanes

  19. Taxanes: Premedication Guidelines

  20. Taxane Hypersensitivity Reactions

  21. Anemia

  22. Differentiating the Taxanes: Efficacy

  23. Pivotal Phase III Trials of PaclitaxelSingle Agent and Combinations

  24. Pivotal Phase III Trials of DocetaxelSingle Agent and Combinations

  25. TAX 311: Paclitaxel versus Docetaxel in Metastatic Breast Cancer

  26. TAX 311: Paclitaxel Versus Docetaxel in Metastatic Breast Cancer – OS

  27. TAX 311: Hematologic Toxicity

  28. TAX 311: Non-Hematologic Toxicity

  29. TAX 311: Quality of Life Analysis

  30. Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Design

  31. Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Results

  32. Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: TTP

  33. Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS

  34. Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS ( ≥ 2nd-line Patients)

  35. nab-Paclitaxel vs Paclitaxel in MBC: Hematologic Toxicities

  36. nab-Paclitaxel vs Paclitaxel in MBC: Non-Hematologic Toxicities

  37. nab-Paclitaxel vs Paclitaxel in MBC: Neuropathy Resolution

  38. Phase II Study of Weekly nab-Paclitaxel in Taxane-Refractory MBC

  39. Taxanes: Cost-effectiveness Model

  40. Cost-effectiveness Model: Methodology (cont.)

  41. Costs per Cycle

  42. Frequency of Grade 3/4 Toxicities (O’Shaughnessy 2003)

  43. Treatment Costs per Toxicity for Taxane Therapy

  44. Cost-effectiveness Ratios

  45. Model Analysis of Total Costs

More Related